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Addison's disease is a well recognised clinical syndrome, but the neurological
syndromes which can be associated with it are more unusual.
CASE HISTORY
A 27-year-old male presented with mild unsteadiness of gait of two years'
duration. Since childhood he had had enuresis and occasional faecal
incontinence. From the age of eight he had had recurrent episodes of upper
abdominal pain and anorexia which had been severe enough on several
occasions to necessitate admission to hospital, although a precise diagnosis of
the cause was never made. Between episodes, his appetite was not good and he
never attained a weight greater than 120 lbs. During his teenage years he
acquired a great fondness for potato crisps and salted peanuts and he often
added copious amounts of salt to his food.
In his early 20s he had a particularly severe episode of anorexia, vomiting and
abdominal pain while on a summer holiday in Spain. Despite feeling exceedingly
weak, he made his way back to London by plane, and, without seeking medical
attention, checked into a hotel where he spent his time in his room drinking a lot
of fluid and eating many packets of potato crisps and peanuts, so that three days
later he was able to emerge feeling more or less back to normal.
Puberty occurred normally in his mid-teens but he became aware of difficulty in
penile erection; this symptom persisted together with the disturbance of bladder
control which had been present since childhood. He became unsteady on his feet
at about the age of 25. His neurological symptoms have not changed significantly
during the three years he has been under observation. He has had no sensory
symptoms in his limbs nor any visual symptoms and, in particular, colour vision
is intact.
He was an adopted child and has no knowledge of his family background.
Examination revealed a thin well -tanned young man with pigmentation ofthe lips
and buccal mucosa. Development of secondary sexual characteristics was
normal. Blood pressure was 120/70 mmHg lying and standing. His speech
function was normal, colour vision unimpaired and function of the cranial nerves
intact. In the limbs there was a mild spasticity of arms and legs together with mild
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weakness of hip flexors and ataxia on heel-shin testing bilaterally. The tendon
reflexes were generally brisk with bilateral extensor plantar responses. On
sensory testing vibration sense was absent to the knees, and position sense
defective at both great toes. Pin prick and light touch were unimpaired. He had a
spastic ataxic gait.
Serum urea and electrolytes, blood count, sedimentation rate, serum B12 and
folic acid levels were all normal. Cerebrospinal fluid analysis and myelogram were
normal. Sensory evoked responses were delayed at spinal and cortical levels.
Motor and sensory conduction in the peripheral nerves were normal. Visual
evoked responses and auditory evoked responses were also normal. CT scan of
the brain was normal.
The diagnosis of primary adrenal insufficiency was confirmed by serum cortisol
levels of 150 nmol/l and 140 nmol/l at 0700 and 2300 h respectively and 140
nmol/l 30 minutes after an intravenous injection of 0.25 mg tetracosactrin
(Synacthen), and a random plasma ACTH of 1150 ng/l (normal < 70). Adrenal
autoantibodies were not detected.
Plasma levels of very long chain (C24 - 30) fatty acids, measured by gas liquid
chromatography,' are shown in the Table.
After replacement therapy with hydrocortisone and fludrocortisone his appetite
and weight have increased, as has his general strength, butsome three years after
diagnosis his neurological symptoms and signs are unchanged.
TABLE
Plasma levels of very long chain fatty acids
Patient Controls*
C22% total fatty acid** 0.773 1.18 ± 0.61
C24% total fatty acid 0.963 0.78 ± 0.32
C25% total fatty acid 0.030 0.03 ± 0.03
C26% total fatty acid 0.028 0.01 ± 0.01
C26 (pg/ml) 0.773 0.33 ± 0.18
C24/C22 1.246 0.84 0.08
C26/C22 0.036 0.01 ± 0.01
*From Moser etal.1 Results as mean ± SD of 22 persons age 12 to 15 years with no known disease
and 28 persons with neurologic or metabolic disorders not related to adrenoleukodystrophy or
adrenomyeloneuropathy.
* *C22 etc refers to the carbon chain length of the fatty acid.
DISCUSSION
The findings of primary adrenocortical failure together with a mild spastic ataxic
paraparesis and an elevated plasma levelofvery long chain fatty acids established
the diagnosis of adrenomyeloneuropathy,2 and to our knowledge this is the first
case described in Ulster.
Adrenomyeloneuropathy is a rare X4linked recessive disorder. Avariant, adreno -
leukodystrophy, was first described in 19233 and both forms may occur in one
family. The first features of adrenomyeloneuropathy are symptoms of adrenal
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insufficiency beginning in the first or second decade followed by the appearance
of a progressive myelopathy during the third or fourth decade,4 and often
accompanied by a cerebellar ataxia and sphincter disturbance as in the present
case. Features of a peripheral neuropathy may also occur. The precise aetiology
of the condition is unknown but the accumulation of saturated unbranched very
long chain fatty acids in tissues and body fluids is characteristic,2 suggesting an
inherited defectinsome enzyme(s) involved infatty acid metabolism. Cytoplasmic
inclusion bodies, which may be detected in the brain, spinal cord, adrenal and
testicular tissue are thought to represent breakdown products of very long chain
fatty acids.5
Although the hypoadrenalism can be satisfactorily treated with corticosteroids as
in Addison's disease, correction of the hypoadrenal state does not modify the
progressive neurological course.2 Perhaps the most remarkable aspect of this
case has been the patient's ability to fend off any serious metabolic catastrophe
for a 20-year period through copious salt ingestion. Salt hunger has long been
recognised as a feature of Addison's disease6 but such prodigious efforts must
be exceptional!
Detection of 'carriers' to facilitate genetic counselling should represent an
important part of the overall management of any inheritable progressive disorder
lacking specific curative therapy. One report suggested that females, hetero-
zygous for the condition, may be identified by abnormal auditory evoked
responses,7 but the finding of normal responses in our patient who has well
developed features of the syndrome must cast doubt on this. A more promising
approach to the detection of heterozygotes lies in the measurement of plasma
very long chain fatty acids, which have been-shown to be elevated in carriers as
well as in patients.1, 2
We are indebted to Dr H W Moser, Director of the John F Kennedy Institute, Baltimore, Maryland, for
measuring plasma fatty acid levels in this patient. We would like to thank Miss Angela Gibney for
typing the manuscript.
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